StemSpan™-ACF Erythroid Expansion Medium
Overview
⦁ Optimized for use with StemSpan™ Erythroid Expansion Supplement
⦁ Produces thousands of CD71+GlyA+ erythroid cells per input CD34+ cell
Related Products
Scientific Resources
Product Documentation
| Document Type | Product Name | Catalog # | Lot # | Language |
|---|---|---|---|---|
|
Document Type
Product Information Sheet
|
Product Name
StemSpan™-ACF Erythroid Expansion Medium
|
Catalog #
09860 |
Lot #
All |
Language
English |
|
Document Type
Safety Data Sheet
|
Product Name
StemSpan™-ACF Erythroid Expansion Medium
|
Catalog #
09860 |
Lot #
All |
Language
English |
Educational Materials (3)
Product Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Data and Publications
Data
Figure 1. Production of Erythroid Cells from Human CB-Derived CD34+ Cells Cultured in StemSpan™ Media Containing StemSpan™ Erythroid Expansion Supplement
(A) Average numbers of erythroid cells generated after culturing purified CD34+ CB cells (n = 5) for 14 days in StemSpan™ SFEM (black bars), SFEM II (grey bars), or StemSpan™-ACF Erythroid Expansion Medium (ACF-E, orange bars) media containing StemSpan™ Erythroid Expansion Supplement (Catalog #02692). Shown are the number of erythroid cells that express CD71 and/or Glycophorin A (GlyA) per input CD34+ cell. (B) The percentages of the different erythroid cell subsets generated in these cultures are shown, including CD71+GlyA+ erythroblasts, immature CD71+GlyA- erythroid progenitor cells and pro-erythroblasts, and CD71-/lowGlyA+ normoblasts. All three media supported the generation of thousands of erythroid cells per CB-derived CD34+ cell plated.
Table 1. Production of Erythroid Cells from Human CB-Derived CD34+ Cells Cultured in StemSpan™ Media Containing StemSpan™ Erythroid Expansion Supplement
Yields and percentages of erythroid cells produced after culturing purified CD34+ CB cells (n = 5) for 14 days in StemSpan™ SFEM, SFEM II or ACF-E media containing Erythroid Expansion Supplement. Erythroid cells were identified by flow cytometry after staining with antibodies against CD71 and GlyA. The % erythroid cells represent the percentage of cells that express CD71 and/or GlyA.
*CI: Confidence Interval.
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
